An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia

Sulforaphane-rich Broccoli Sprout Extract for Schizophrenia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01716858

Enrollment

Registered

2012-10-30

Start date

2012-10-31

Completion date

2014-03-31

Last updated

2015-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Keywords

Schizophrenia, Sulforaphane, Psychosis, Cognition, Oxidative stress, Antioxidant, Anti-inflammatory

Brief summary

Accumulating evidence suggests a role of oxidative stress in the pathophysiology of schizophrenia. The potent antioxidant sulforaphane (SFN) is an organosulfur compound derived from a glucosinolate precursor found in cruciferous vegetables such as broccoli, Brussels sprouts and cabbage. The protection afforded by SFN is thought to be mediated via activation of the NF-E2-related factor-2 (Nrf2) pathway and subsequent up-regulation of phase II detoxification enzymes and antioxidant proteins, through an enhancer sequence referred to as the electrophilic responsive element or antioxidant responsive element. Recently, we reported that SFN could attenuate behavioral abnormalities in mice after the NMDA receptor antagonist phencyclidine. Considering the potent antioxidant effects of SFN, we have a hypothesis that SFN would be a potential therapeutic drug for schizophrenia. The purpose of this study is to determine whether SFN-rich broccoli sprout extract have beneficial effects in patients with schizophrenia.

Interventions

DIETARY_SUPPLEMENTSulforaphane-rich Broccoli Sprout Extract

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Schizophrenia for DSM-IV TR criteria * Patients are treated with an antipsychotic drug (risperidone, olanzapine, quetiapine, perospirone, aripiprazole, blonanserin, paliperidone). * Patients are stable for 4-weeks for antipsychotic medication.

Exclusion criteria

* Patients treated with clozapine * Patients treated with two or more antipsychotic drugs * Pregnant or breast-feeding women * Patients treated with sulforaphane for more than 8-weeks in the past.

Design outcomes

Primary

Measure	Time frame
Positive and Negative Syndrome Scale (PANSS)	Change from baseline in PANSS scores at 8-weeks

Secondary

Measure	Time frame
Cognition using CogState Research Battery	Change from baseline in the scores of the battery at 8-weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026